EcoDrugPlus

Purinergic Receptor P2y2

Ensembl ID : ENSECRG00000001644
Gene Symbol: P2RY2
3 Cross references
198 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSECRG00000001687
Gene Symbol: P2RY2
1 Cross references
198 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSECRG00000013459
Gene Symbol: P2RY4
3 Cross references
168 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSECRG00000001625
Gene Symbol: P2RY6
1 Cross references
183 Possible Orthologues:

Receptor Activity-Modifying Protein 1-Like

Ensembl ID : ENSECRG00000014413
Gene Symbol: LOC114656402
3 Cross references
252 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSECRG00000001089
Gene Symbol: RIPK1
3 Cross references
198 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSECRG00000019578
Gene Symbol: RPTOR
3 Cross references
214 Possible Orthologues:

Renin

Ensembl ID : ENSECRG00000003667
Gene Symbol: REN
3 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSECRG00000018102
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSECRG00000004628
Gene Symbol: LOC114651509
3 Cross references
215 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSECRG00000016474
Gene Symbol: RARB
3 Cross references
451 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSECRG00000008381
Gene Symbol: RARG
3 Cross references
453 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).